Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
chloroquine 2 rheumatologydiseasesdrugs
hydroxychloroquine 2 rheumatologydiseasesdrugs
infliximab 1 rheumatologydiseasesdrugs
methotrexate 4 rheumatologydiseasesdrugs
rheumatoid arthritis 7 rheumatologydiseases
anakinra 15 rheumatologydiseasesdrugs
arthritis 12 rheumatologydiseases
methylprednisolone 3 rheumatologydiseasesdrugs
prednisolone 3 rheumatologydiseasesdrugs
prednisone 1 rheumatologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
anakinra 6508 observed (metformin 500mg once/daily). Fasting insulin levels were increased following treatment with anakinra : 34pmoles/liter at baseline; 43 pmoles/liter at three months and 69pmoles/liter at six months, respectively.
anakinra 7385 glucose (g) and glycosylated hemoglobin (h) concentrations in our two patients at the beginning of anakinra treatment and after three and six months of follow-up.Case report twoA 74-year-old Caucasian man with
anakinra 8882 22mm, respectively. In addition, although oral anti-diabetic therapy was tapered off eight days after anakinra introduction due to a poor compliance, an improvement in glycemic control was noted (his FPG and HbA1c
anakinra 9346 45.36mmol/mol, 6.3% (4.8-5.9%), respectively). His fasting insulin level was increased following treatment with anakinra : 36pmoles/liter at baseline, 53pmoles/liter at three months and 77pmoles/liter at six months, respectively.
anakinra 9803 diet/caloric intake did not modify during the follow-up. No side effects were observed.DiscussionWe show that anakinra , prescribed for the treatment of relapsing RA in two rheumatic patients with associated T2DM, controls
anakinra 10216 [[7]].In both case studies, our patients reached a sustained DAS28 remission after introduction of anakinra , without any side effects observed during the follow-up periods. IL-1β is highly expressed in RA, promoting
anakinra 11369 and T2DM) displayed a much higher risk of CVD and related mortality.In our patients, we observed that anakinra administered to treat RA controlled their metabolic disorder. A significant reduction of both FPG and
anakinra 12876 drug intake, while the other patient discontinued the specific antidiabetic therapy. In this setting, anakinra was able to determine both a stable DAS28 remission and a glycemic control after six months and that
anakinra 13880 double blind, parallel-group trial, involving 70 T2DM patients randomly assigned to receive 100mg of anakinra or placebo. At 13 weeks, the anakinra group showed an improvement of HbA1c levels, the C-peptide secretion
anakinra 13918 involving 70 T2DM patients randomly assigned to receive 100mg of anakinra or placebo. At 13 weeks, the anakinra group showed an improvement of HbA1c levels, the C-peptide secretion was enhanced and a reduction in
anakinra 14557 and suggesting an improvement of β-cell function. In this context, it has been recently shown that anakinra is able to increase insulin secretion [[14]], and this insulin availability may explain its metabolic
anakinra 14713 and this insulin availability may explain its metabolic effects.Recently, Moran et al. reported that anakinra therapy was not effective in type 1 diabetes (T1DM) patients [[15]]. It must be pointed out that the
anakinra 15155 inhibit the pathogenesis of T1DM [[5],[15]].ConclusionsIn conclusion, we report the positive effects of anakinra for two patients with RA associated with T2DM reaching the therapeutic targets of both the diseases,
anakinra 15490 further specifically designed studies must be performed to evaluate the safety and long-term efficacy of anakinra in patients with RA associated with T2DM, and the subsequent reduction of CV events in this population.
anakinra 15726 open, randomized, controlled, double-arm, multi-center study, whose primary endpoint is the efficacy of anakinra in controlling the signs and symptoms of T2DM in patients with RA affected by this metabolic disorder,
chloroquine 4147 seronegative RA was diagnosed. Combination therapy with methotrexate (15mg/weekly) (TEVA, Israel), hydroxy chloroquine (400mg/daily) (Sanofi, Italy) and a low dose of prednisone (10mg/daily) (Bruno Farmaceutici, Italy)
chloroquine 7598 eight-year history of RA, treated by a combination therapy with methotrexate (15mg/weekly), hydroxy chloroquine (200mg/daily) and methylprednisolone (Pfizer, Italy) (16mg/daily at the beginning, progressively tapered
hydroxychloroquine 4140 seronegative RA was diagnosed. Combination therapy with methotrexate (15mg/weekly) (TEVA, Israel), hydroxychloroquine (400mg/daily) (Sanofi, Italy) and a low dose of prednisone (10mg/daily) (Bruno Farmaceutici, Italy)
hydroxychloroquine 7591 with an eight-year history of RA, treated by a combination therapy with methotrexate (15mg/weekly), hydroxychloroquine (200mg/daily) and methylprednisolone (Pfizer, Italy) (16mg/daily at the beginning, progressively tapered
infliximab 5313 DAS28, SDAI and PG-VAS scores were 6.27, 34.6 and 80mm, respectively), her anti-TNF-α treatment with infliximab (MSD, USA) was discontinued. Both her methotrexate and steroids dosage remained stable; the hydrossicloroquine
methotrexate 4097 4.5, 28 and 67mm, respectively, and active seronegative RA was diagnosed. Combination therapy with methotrexate (15mg/weekly) (TEVA, Israel), hydroxychloroquine (400mg/daily) (Sanofi, Italy) and a low dose of prednisone
methotrexate 5362 80mm, respectively), her anti-TNF-α treatment with infliximab (MSD, USA) was discontinued. Both her methotrexate and steroids dosage remained stable; the hydrossicloroquine was discontinued due to poor compliance.
methotrexate 7563 twoA 74-year-old Caucasian man with an eight-year history of RA, treated by a combination therapy with methotrexate (15mg/weekly), hydroxychloroquine (200mg/daily) and methylprednisolone (Pfizer, Italy) (16mg/daily at
methotrexate 8541 (Pfizer, Italy) employed. Anakinra (100mg/daily subcutaneously) (Sobi, Sweden) was started, in addition to methotrexate (10mg/weekly) (TEVA, Israel) and methylprednisolone (3-4mg daily) (Pfizer, Italy), leading to clinical
methylprednisolone 7628 treated by a combination therapy with methotrexate (15mg/weekly), hydroxychloroquine (200mg/daily) and methylprednisolone (Pfizer, Italy) (16mg/daily at the beginning, progressively tapered to 3 to 4mg/daily), obtaining a
methylprednisolone 8398 Farmaceutici, Italy) (FPG level 310mg/dL, HbA1c level 73mmol/mol, 8.8% (4.8-5.9%)) despite the lower levels of methylprednisolone (3 to 4mg/daily) (Pfizer, Italy) employed. Anakinra (100mg/daily subcutaneously) (Sobi, Sweden) was
methylprednisolone 8587 subcutaneously) (Sobi, Sweden) was started, in addition to methotrexate (10mg/weekly) (TEVA, Israel) and methylprednisolone (3-4mg daily) (Pfizer, Italy), leading to clinical improvement within a few days.At his three-month
prednisolone 7634 by a combination therapy with methotrexate (15mg/weekly), hydroxychloroquine (200mg/daily) and methyl prednisolone (Pfizer, Italy) (16mg/daily at the beginning, progressively tapered to 3 to 4mg/daily), obtaining a
prednisolone 8404 Italy) (FPG level 310mg/dL, HbA1c level 73mmol/mol, 8.8% (4.8-5.9%)) despite the lower levels of methyl prednisolone (3 to 4mg/daily) (Pfizer, Italy) employed. Anakinra (100mg/daily subcutaneously) (Sobi, Sweden) was
prednisolone 8593 subcutaneously) (Sobi, Sweden) was started, in addition to methotrexate (10mg/weekly) (TEVA, Israel) and methyl prednisolone (3-4mg daily) (Pfizer, Italy), leading to clinical improvement within a few days.At his three-month
prednisone 4207 methotrexate (15mg/weekly) (TEVA, Israel), hydroxychloroquine (400mg/daily) (Sanofi, Italy) and a low dose of prednisone (10mg/daily) (Bruno Farmaceutici, Italy) was prescribed. She experienced a long clinical remission (her
Select Disease Character Offset Disease Term Instance
arthritis 97 Title: Journal of Medical Case ReportsEfficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literaturePiero RuscittiPaola CiprianiLuca
arthritis 473 6/2015Publication date (pmc-release): 6/2015Publication date (collection): /2015AbstractIntroductionRheumatoid arthritis is an autoimmune arthritis in which two inflammatory cytokines, tumor necrosis factor-α and interleukin-1β,
arthritis 500 6/2015Publication date (collection): /2015AbstractIntroductionRheumatoid arthritis is an autoimmune arthritis in which two inflammatory cytokines, tumor necrosis factor-α and interleukin-1β, play a critical role
arthritis 950 peripheral insulin resistance and type 2 diabetes mellitus is increased among patients with rheumatoid arthritis . In addition, several studies have shown that type 2 diabetes mellitus may be considered an interleukin-1β
arthritis 1346 describe the case of a 58-year-old Caucasian woman and a 74-year-old Caucasian man with rheumatoid arthritis associated with type 2 diabetes mellitus. In these patients, the inhibition of interleukin-1β not only
arthritis 1493 mellitus. In these patients, the inhibition of interleukin-1β not only induced remission for rheumatoid arthritis , but successfully controlled their metabolic status.ConclusionsWe report the positive effects of the
arthritis 1664 status.ConclusionsWe report the positive effects of the inhibition of interleukin-1 in two patients with rheumatoid arthritis associated with type 2 diabetes mellitus, with both reaching the therapeutic targets of their diseases
arthritis 2002 targeting interleukin-1 might be considered a good therapeutic option for the treatment of rheumatoid arthritis associated with type 2 diabetes mellitus.IntroductionInterleukin-1β (IL-1β) and tumor necrosis factor-α
arthritis 2196 tumor necrosis factor-α (TNF-α) play a critical role in the induction and progression of rheumatoid arthritis (RA), and the efficacy of therapies targeting these two inflammatory cytokines confirms their prominent
arthritis 3191 woman was referred to our clinic due to the insidious onset, in previous months, of arthralgias and arthritis . Her symptoms involved wrists, hands, shoulders and knees. She also reported notable morning stiffness
arthritis 4488 respectively, after one year).She experienced a new disease flare-up after two years, characterized by multiple arthritis (wrists, hands and knees) and an increase of morning stiffness and fatigue (her DAS28, SDAI and PG-VAS
arthritis 5146 drug (metformin 500mg trice/daily). One year later, following a new flare-up of her disease involving arthritis of her wrists, hands, elbows, shoulders and knees (her DAS28, SDAI and PG-VAS scores were 6.27, 34.6
rheumatoid arthritis 86 Title: Journal of Medical Case ReportsEfficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literaturePiero RuscittiPaola CiprianiLuca
rheumatoid arthritis 939 prevalence of peripheral insulin resistance and type 2 diabetes mellitus is increased among patients with rheumatoid arthritis . In addition, several studies have shown that type 2 diabetes mellitus may be considered an interleukin-1β
rheumatoid arthritis 1335 presentationWe describe the case of a 58-year-old Caucasian woman and a 74-year-old Caucasian man with rheumatoid arthritis associated with type 2 diabetes mellitus. In these patients, the inhibition of interleukin-1β not only
rheumatoid arthritis 1482 diabetes mellitus. In these patients, the inhibition of interleukin-1β not only induced remission for rheumatoid arthritis , but successfully controlled their metabolic status.ConclusionsWe report the positive effects of the
rheumatoid arthritis 1653 status.ConclusionsWe report the positive effects of the inhibition of interleukin-1 in two patients with rheumatoid arthritis associated with type 2 diabetes mellitus, with both reaching the therapeutic targets of their diseases
rheumatoid arthritis 1991 suggest that targeting interleukin-1 might be considered a good therapeutic option for the treatment of rheumatoid arthritis associated with type 2 diabetes mellitus.IntroductionInterleukin-1β (IL-1β) and tumor necrosis factor-α
rheumatoid arthritis 2185 (IL-1β) and tumor necrosis factor-α (TNF-α) play a critical role in the induction and progression of rheumatoid arthritis (RA), and the efficacy of therapies targeting these two inflammatory cytokines confirms their prominent

You must be authorized to submit a review.